Landmark NIH allergy study shows immunotherapy successfully desensitizes 71% of young children with severe peanut allergy, with 21% also achieving remission.
The new program, a part of the All of US Research Program, will seek to develop algorithms to predict responses to each individual's diet. The effort will recruit 10,000 people from diverse backgrounds as it looks to create tools to provide individuals with personal dietary recommendations.
The program seeks to enroll five million participants as it looks to develop a broad view of the health of the country’s population while developing new ways to prevent and treat diseases and health conditions such as cancer, Alzheimer’s disease, heart disease, arthritis, diabetes, and stroke.
A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.
Cancer Research UK’s Centre for Drug Development will sponsor and manage the trial and Roche will provide the first five targeted therapies for evaluation.
Central to the deal was GeneDx’s rare disease diagnosis and clinical exome sequencing capabilities along with data from more than 300,000 exomes and 2.1 million annotated patient phenotypes.
Large-scale study strengthens link between Epstein-Barr Virus (EBV) infection and multiple sclerosis (MS). Prior EBV infection raises risk of MS 32-fold.
New findings suggest engineered DNA-free virus-like particles are an attractive alternative to other delivery strategies for the in vivo or ex vivo delivery of base editors, nucleases, and other proteins of therapeutic interest.
Of note in the recently released updated guidance, was information on the use of a human monoclonal antibody treatment regimen as a preventive measure against contracting COVID-19.
A combination of splice-switching antisense oligonucleotides could work against a common CFTR mutation that causes a severe form of cystic fibrosis, according to new research.